Show simple item record

dc.contributorCompiled by the New Jersey State Libraryen_US
dc.date.accessioned2019-08-01T13:27:48Z
dc.date.available2019-08-01T13:27:48Z
dc.identifier.urihttp://hdl.handle.net/10929.1/26498
dc.description.abstractYear: 2016; Chapter: 73
dc.titleClarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.
dc.typeLegislative Historyen_US
lg.yearEnacted2016en_US
lg.chapter73en_US
lg.billNumberS2024en_US
lg.synopsisClarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.
lg.NJSA24:6B-1 & 24:6B-2en_US
lg.njlhidL2016c73en_US
lg.titleClarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.


Files in this item

Files in this item

FilesSizeFormatViewDescription
L2016c73.pdf1.739MbPDFThumbnailL2016c73

This item appears in the following Collection(s)

  • 2016
    New Jersey Legislative Histories from 2016

Show simple item record